Evaluating Previous ARDS Preclinical & Clinical Trial Designs to Assess the Optimum Path to Take for Future Studies: TLR4 Inhibitors with a Monoclonal Antibody to Treat ARDS

Time: 8:25 am
day: Day One


  • Highlighting the mechanism of action of EB05, a TLR4 inhibitor
  • Reviewing the components of preclinical study designs which allowed or inhibited progression to the clinic
  • Delving into past clinical trial designs to enable the success of current and future
    clinical trials